The burden and costs of prevention and management of genital disease caused by HPV in women: A population‐based registry study in Finland
暂无分享,去创建一个
K. Auranen | M. Lehtinen | T. Leino | Simopekka Vänskä | M. Linna | T. Kilpi | P. Nieminen | H. Salo | Petri Tiihonen
[1] Y. Qiao,et al. EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease , 2012, International journal of cancer.
[2] S. Lönnberg,et al. Age-Specific Effectiveness of the Finnish Cervical Cancer Screening Programme , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[3] S. Hibbitts. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial , 2012, Journal of Family Planning and Reproductive Health Care.
[4] S. Lönnberg,et al. Validation of histological diagnoses in a national cervical screening register , 2012, Acta oncologica.
[5] M Arbyn,et al. Worldwide burden of cervical cancer in 2008. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] H. Jessen,et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.
[7] D. Lowy,et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. , 2011, The Lancet. Oncology.
[8] N. Kiviat,et al. Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[9] S. Franceschi,et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.
[10] Joakim Dillner,et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.
[11] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[12] R. Kurman,et al. Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors , 2009, Obstetrics and gynecology.
[13] L. Irgens,et al. Pregnancy outcome in women before and after cervical conisation: population based cohort study , 2008, BMJ : British Medical Journal.
[14] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[15] S. Kjaer,et al. Acquisition and Persistence of Human Papillomavirus Infection in Younger Men: A Prospective Follow-up Study among Danish Soldiers , 2005, Cancer Epidemiology Biomarkers & Prevention.
[16] J. Baseman,et al. The epidemiology of human papillomavirus infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[17] M. Lehtinen,et al. High prevalence of HPV among female students in Finland , 2005, Scandinavian journal of infectious diseases.
[18] K. Holmes,et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. , 2004, The Journal of infectious diseases.
[19] Michal Abrahamowicz,et al. The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] M. Plummer,et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.
[21] L. Koutsky,et al. Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis , 2002, Sexually transmitted diseases.
[22] M. Hakama,et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: Recent increase in cervical cancer incidence , 1999, International journal of cancer.
[23] L Beardsley,et al. Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.
[24] C. Wheeler,et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[25] Edson Duarte Moreira Júnior,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.
[26] K. Louhivuori. Effect of a mass screening program on the risk of cervical cancer. , 1991, Cancer detection and prevention.
[27] S. Wetten,et al. Genital warts and cost of care in England , 2011, Sexually Transmitted Infections.